Caprock Group’s Viking Therapeutics VKTX Stock Holding History

Caprock Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,610	Closed	-$542K	–	913
2024 Q1	$542K	Buy	+6,610	New	+$294K	0.03%	387

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Caprock Group's VKTX Position: Q2 2024 in Review

Caprock Group sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 6,610 shares — an estimated $542K sold.

Caprock Group first reported a position in VKTX in Q1 2024 and held it in 1 quarter. The position peaked at $542K in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

Caprock Group reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
Caprock Group sold 6,610 Viking Therapeutics shares in Q2 2024, an estimated $542K.
Caprock Group first reported a position in Viking Therapeutics in Q1 2024 and held it in 1 quarter.
Caprock Group's Viking Therapeutics position peaked at $542K in Q1 2024.
387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Caprock Group's 13F filing for Q2 2024, filed 6 Aug 2024.